3.65
-0.82%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Immuneering
From its filings with the US Securities and Exchange Commission
Immuneering is based in Cambridge, Massachusetts and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker IMRX. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2023, it reported revenue of $0.
We are a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive. We are developing and seeking to commercialize an entirely new category of anti-cancer medicines, Deep Cyclic Inhibitors, which we believe have the potential to be more effective and better tolerated targeted therapies.
Deep Cyclic Inhibition® ("DCI") is a novel mechanism that aims to deprive tumor cells of the sustained proliferative signaling required for rapid growth, while sparing healthy cells through a cadenced, normalized level of signaling. Our Deep Cyclic Inhibitors inhibit clinically-validated core signaling pathways, such as the mitogen-activated protein kinase ("MAPK") pathway. Our novel approach is designed to improve durability and tolerability, and differentiates us from chronically targeted precision therapies, which are generally limited by toxicity, resistance and/or application to specific mutations only.
Our lead product candidate, atebimetinib (IMM-1-104), is an oral, once-daily Deep Cyclic Inhibitor of mitogen-activated protein kinase kinase ("MEK"), designed to improve durability and tolerability across many cancer indications, including MAPK pathway-driven tumors such as pancreatic cancer. We are currently in the process of initiating a Phase 3 clinical trial of atebimetinib, which we call the MAPKeeper 301 trial, to evaluate atebimetinib in combination with modified gemcitabine/nab-paclitaxel ("mGnP") in first-line pancreatic cancer patients. We expect to dose the first patient in the MAPKeeper 301 trial in mid-2026.
Quoted from its 10-K, filed 6 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 30 Jul 2021
- Employees
- 53
- Website
- immuneering.com ↗
- Head office
- 245 MAIN STREET, SECOND FLOOR, CAMBRIDGE, MA, 02142
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Leadership
Pay as last reported
- Ms. Ann BermanIndependent Chairman of the Board$128,740
- Dr. Benjamin ZeskindPresident, Chief Executive Officer, Co-Founder, Director, since 2008$1.9m
- Ms. Leah NeufeldChief People Officer
- Ms. Mallory MoralesChief Accounting Officer, Treasurer
- Dr. Brett HallChief Scientific Officer$1.4m
- Mr. Harold BrakewoodChief Business Officer$1.5m
- Dr. Igor MatushanskyChief Medical Officer
- Mr. Michael BookmanChief Legal Officer, Secretary$1.1m
- Mr. Robert CarpenterIndependent Director$84,740
- Mr. Peter FeinbergIndependent Director$91,240
- Dr. Diana HausmanIndependent Director$92,740
- Ms. Laurie KeatingIndependent Director$97,240
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 62
- Environment
- 68
- Social
- 59
- Governance
- 59
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Immuneering Corp's lead product IMM-1-104 is in Phase I/IIa clinical trials for RAS-mutated solid tumors.
- The company's platform uses Bioinformatics and 3D Tumor Modeling for drug development.
- Immuneering Corp has two product candidates IMM-1-104 and IMM-6-415 in development stages.
Weaknesses
- Immuneering Corp has only 53 employees, which is a small team for a clinical-stage biotech company.
- The company's IPO was on 30 July 2021, indicating a relatively recent market entry.
- Immuneering Corp's pipeline includes only two main product candidates with limited diversity.
Opportunities
- The universal-RAS therapy market for cancer patients is growing with increasing RAS mutation prevalence.
- Immuneering Corp's platform can be applied to other cancer types beyond RAS-mutated tumors.
- The company can expand its pipeline with additional small molecule drug discovery programs.
Threats
- Competition from other biotech companies developing similar RAS-targeted therapies.
- Regulatory hurdles in clinical trials for new cancer treatments could delay approvals.
- The high costs of developing new cancer therapies may strain financial resources.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.